Market Place
Sourcing Support
IGC Pharma Joins Fireside Chat With Ascendiant Capital Markets
12 Feb 2026 //
PHARMIWEB
IGC Reveals Equity Research Update From Alliance Global Partners
10 Feb 2026 //
PHARMIWEB
IGC Pharma Expands Phase 2 Alzheimer`s Trial In Colombia`s Top
09 Feb 2026 //
PHARMIWEB
IGC Pharma Enrolls 70% In CALMA Trial For Alzheimer`s Agitation
02 Feb 2026 //
PHARMIWEB
IGC Pharma Expands CALMA Trial To Dominion Medical Associates
12 Jan 2026 //
PHARMIWEB
IGC Pharma Aligns FY to Calendar Year for Enhanced U.S. Reporting
06 Jan 2026 //
ACCESSWIRE
IGC Pharma Raises Capital To Advance IGC-AD1 Phase 2 Trial
05 Jan 2026 //
PHARMIWEB
IGC Pharma Obtains New US Patent For Pharmaceutical Cannabinoids
19 Dec 2025 //
PHARMIWEB
IGC Pharma Benefits From Federal Shift To Schedule III
15 Dec 2025 //
PHARMIWEB
Ascendiant Capital Raises IGC Pharma Price Target
10 Dec 2025 //
PHARMIWEB
IGC Pharma Reaches 65% Enrollment Milestone In Alzheimer Trial
09 Dec 2025 //
PHARMIWEB
IGC Pharma Releases Landmark Alzheimer`s Caregiver Book
02 Dec 2025 //
PHARMIWEB
IGC Pharma Utilizes MINT-AD To Uncover Socioeconomic Factors
25 Nov 2025 //
PHARMIWEB
USPTO Grants IGC Pharma Patent Covering IGC-AD1
13 Nov 2025 //
PHARMIWEB
IGC Pharma To Host Fiscal 2026 Shareholder Update Call
10 Nov 2025 //
PHARMIWEB
IGC Pharma Expands Ai-Powered Drug Discovery In-Silico Pipeline
03 Nov 2025 //
PHARMIWEB
IGC Pharma Reaches Semi-Finals in Alzheimer’s AI Prize
22 Oct 2025 //
PR NEWSWIRE
IGC Pharma Expands CALMA Trial To University Of South Florida
14 Oct 2025 //
ACCESSWIRE
IGC Pharma Announces 2025 Stockholders Meeting Outcomes
10 Oct 2025 //
ACCESSWIRE
IGC Pharma`s IGC-1C: Shows Promise In Disrupting Alzheimer
07 Oct 2025 //
ACCESSWIRE
IGC Pharma Adds CALMA Ph 2 Alzheimer’s Trial Site
29 Sep 2025 //
ACCESSWIRE
IGC Pharma Reports 50% Enrollment in Ph 2 CALMA Alzheimer`s Trial
22 Sep 2025 //
ACCESSWIRE
IGC Pharma Win 3rd NIA Award for Alzheimer`s Detection Excellence
09 Sep 2025 //
PHARMAWEB
IGC Pharma Gets Patent Nod for Microdose in Tourette`s Syndrome
28 Aug 2025 //
ACCESSWIRE
IGC Pharma Receives Positive Coverage Report, Price Target
27 Aug 2025 //
PHARMAWEB
IGC Pharma Boosts CALMA Phase 2 Trial at Lynn Health Science
25 Aug 2025 //
ACCESSWIRE
IGC Pharma Q1 2026 Financial Results; Phase 2 Alzheimer`s Trial
19 Aug 2025 //
ACCESSWIRE
IGC Pharma`s Pipeline Shows Promise on IGC-M3 & IGC-AD1
12 Aug 2025 //
ACCESSWIRE
IGC Pharma reports IGC-M3`s efficacy against Alzheimer
05 Aug 2025 //
ACCESSWIRE
IGC Pharma Launches MINT-AD AI platform to Predict Alzheimer
10 Jul 2025 //
ACCESSWIRE
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update
27 Jun 2025 //
ACCESSWIRE
IGC Pharma Expands CALMA Trial With Tekton Site in Oklahoma
23 Jun 2025 //
ACCESSWIRE
IGC Pharma Taps Puerto Rico Site For Alzheimer’s CALMA Trial
22 May 2025 //
ACCESSWIRE
IGC Pharma Presents Genetic Toxicology Data at 2025 Meeting
12 May 2025 //
ACCESSWIRE
IGC Pharma Welcomes Strategic Investment from Advisors
24 Apr 2025 //
ACCESSWIRE
IGC Pharma Welcomes Industry Leaders to Alzheimer Advisory Board
21 Apr 2025 //
ACCESSWIRE
IGC Pharma Expands CALMA Alzheimer`s Trial at Butler Hospital
08 Apr 2025 //
ACCESSWIRE
IGC Pharma Expands CALMA Phase 2 Trial with Miami Jewish Health
01 Apr 2025 //
ACCESSWIRE
IGC Pharma`s Phase 2 Trial Shows Reduced Sleep Disturbances
26 Mar 2025 //
ACCESSWIRE
IGC Pharma Expands CALMA Phase 2 Trial with Canadian Hamilton
20 Mar 2025 //
ACCESSWIRE
IGC Pharma Expands Calma Trial with BayCare in Florida
17 Mar 2025 //
ACCESSWIRE
IGC Pharma Gets Ascendiant Coverage, PT Raised To $4.25
12 Mar 2025 //
ACCESSWIRE
IGC Pharma Update by AGP on Alzheimer`s Phase 2 CALMA Results
10 Mar 2025 //
ACCESSWIRE
IGC Pharma Expands AI Platform for Alzheimer`s Detection
04 Mar 2025 //
ACCESSWIRE
IGC Pharma Named Top 15 Finalist For Alzheimer`s Detection
28 Jan 2025 //
PHARMAWEB
IGC Pharma Reports Phase 2 Interim Results for IGC-AD1 in Alzheimer’s
25 Nov 2024 //
BUSINESSWIRE
IGC Pharma Announces New IGC-AD1 Alzheimer`s Data
18 Sep 2024 //
BUSINESSWIRE
IGC Pharma Advances IGC-AD1 Toward Trials for Alzheimer`s Anti-Amyloid Treatment
04 Sep 2024 //
BUSINESSWIRE
IGC Announces Results of its 2024 Annual Stockholders Meeting
26 Aug 2024 //
BUSINESSWIRE
IGC Pharma`s IGC-1C Targets Tau Protein In Alzheimer`s
22 Aug 2024 //
BUSINESSWIRE
IGC Pharma Expands Portfolio With Potential GLP-1 Agonist IGC-1A
20 Aug 2024 //
BUSINESSWIRE
IGC Pharma Reports First Quarter Fiscal 2025 Results
08 Aug 2024 //
BUSINESSWIRE
IGC Pharma Gets "Buy" Rating From Alliance Global Partners
18 Jul 2024 //
BUSINESSWIRE
TGR-63 Shows Blood-Brain Barrier Permeability And Safety Profile
09 Jul 2024 //
BUSINESSWIRE
IGC Pharma`s TGR-63 Shows Promise in Reducing Alzheimer`s Amyloid Plaque
25 Jun 2024 //
BUSINESSWIRE
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
25 Jun 2024 //
BUSINESSWIRE
IGC Pharma To Participate In Fireside Chat With Ascendiant Capital Markets
18 Jun 2024 //
BUSINESSWIRE
IGC Pharma Publishes Study In European Society Of Medicine Investigating
10 Jun 2024 //
BUSINESSWIRE
IGC`s announces patient enrollment at Neurostudies in Ph 2 trial investg IGC-AD1
29 May 2024 //
INDIANPHARMAPOST
IGC Pharma: Patient Enrollment In IGC-AD1 Alzheimer`s Phase 2 Trial
28 May 2024 //
BUSINESSWIRE
